Assessment Of Anti-Inflammatory Cytokine Interleukin-10 In Mild Cognitive Impairment In Elderly

Document Type : Original Article


1 Department of Internal Medicine, Faculty of Medicine, University of Alexandria, Alexandria, Egypt

2 Department of Internal Medicine, Faculty of Medicine, University of Alexandria, Alexandria, Egypt.

3 Department of Clinical and Chemical Pathology, Faculty of Medicine, Alexandria University, Egypt


Background: Mild cognitive impairment (MCI) is decline and disturbance of cognitive, little impairment of complex skills, ability to conduct ordinary daily functions, and the absence of dementia are all features of MCI. Interleukin-10 (IL-10) has anti-inflammatory effects and may suppress neurodegenerative disorders.
Objective: This study aimed to investigate the possible association between serum interleukin 10 (IL-10) levels and mild cognitive impairment (MCI) in the elderly population.
Material and methods: The study was carried out on 90 subjects aged 65 years or older] divided into Group I (MCI patients): including 45 patients. in Group II (Control): which included 45 subjects with normal cognition. All subjects underwent detailed history taking, clinical examination, and assessment of cognitive function. Laboratory investigations included: Serum interleukin-10(IL-10), C-reactive protein (CRP), ESR, CBC, fasting blood glucose (FBS), postprandial blood glucose (PPS), urea, creatinine, and liver enzyme levels.
Results: IL-10 levels in the MCI group ranged from 4.60 – 16.31 with a mean value (S.D) of 9.75 ± 2.26. IL-10 among the control group ranged from 4.91 – to 12.15 with a mean value (S. D) of 8.87 ± 1.80.IL-10 was significantly higher among the MCI group (p=0.044)
Conclusion: There was a statistically significant difference between the serum levels of IL-10 in patients with MCI and controls.


  1. Alzheimer's Association. Mild Cognitive Impairment (MCI)[Internet]. Chicago: Alzheimer's Association; 2019 Dec 19. Available from: dementia/related conditions/mild-cognitive-impairment.
  2. DeCarli C. Mild cognitive impairment: prevalence, prognosis, etiology, and treatment. Lancet Neurol 2003; 2(1):15-21.
  3. Petersen R.C. Mild Cognitive Impairment. Contin. (Minneap Minn) 2016; 22:404–18.
  4. Roberts R, Knopman DS. Classification and epidemiology of MCI. Clin Geriatr Med 2013; 29(4):753-72.
  5. Fougère B, Boulanger E, Nourhashémi F, Guyonnet S, Cesari M. Chronic Inflammation: Accelerator of Biological Aging. J Gerontol A Biol Sci Med Sci 2017; 72(9):1218-25.
  6. Zhang B, Gaiteri C, Bodea LG, Wang Z, McElwee J, Podtelezhnikov AA, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell 2013; 153(3):707-20.
  7. Bradl M, Hohlfeld R. Molecular pathogenesis of neuroinflammation. J Neurol Neurosurg Psychiatry 2003; 74(10):1364-70.
  8. Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC. CNS immune privilege: hiding in plain sight. Immunol Rev 2006; 213:48-65.
  9. Haroutunian V, Hoffman LB, Beeri MS. Is there a neuropathology difference between mild cognitive impairment and dementia? Dialogues Clin Neurosci 2009; 11(2):171-9.
  10. Patel NS, Paris D, Mathura V, Quadros AN, Crawford FC, Mullan MJ. Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease. J Neuroinflammation 2005; 2(1):9.
  11. Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. Nat Rev Immunol 2014; 14(7):463-77.
  12. Bruno MA, Mufson EJ, Wuu J, Cuello AC. Increased matrix metalloproteinase 9 activity in mild cognitive impairment. J Neuropathol Exp Neurol 2009; 68(12):1309-18.
  13. Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes the development of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003; 74(9):1200-5.
  14. Popp J, Bacher M, Kölsch H, Noelker C, Deuster O, Dodel R, et al. Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease. J Psychiatr Res 2009; 43(8):749-53.
  15. Rea IM, Gibson DS, McGilligan V, McNerlan SE, Alexander HD, Ross OA. Age and Age-Related Diseases: Role of Inflammation Triggers and Cytokines. Front Immunol 2018; 9:586.
  16. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19:683-765.
  17.  Kwilasz AJ, Grace PM, Serbedzija P, Maier SF, Watkins LR. The therapeutic potential of interleukin-10 in neuroimmune diseases. Neuropharmacology 2015; 96(Pt A):55-69.
  18. McKinstry KK, Strutt TM, Buck A, Curtis JD, Dibble JP, Huston G, et al. IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenges. J Immunol 2009; 182(12):7353-63.
  19. Heine G, Drozdenko G, Grün JR, Chang HD, Radbruch A, Worm M. Autocrine IL-10 promotes human B-cell differentiation into IgM- or IgG-secreting plasmablasts. Eur J Immunol 2014; 44(6):1615-21.
  20. Ng TH, Britton GJ, Hill EV, Verhagen J, Burton BR, Wraith DC. Regulation of adaptive immunity; the role of interleukin-10. Front Immunol 2013; 4:129.
  21. Chinen T, Kannan AK, Levine AG, Fan X, Klein U, Zheng Y, et al. An essential role for the IL-2 receptor in T(reg) cell function. Nat Immunol 2016; 17(11):1322-33.
  22. Huang S, Ullrich SE, Bar-Eli M. Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. J Interferon Cytokine Res 1999; 19(7):697-703.
  23. Califone NA, Ford CB, Marino S, Mattila JT, Gideon HP, Flynn JL, et al. Computational modeling predicts IL-10 control of lesion sterilization by balancing early host immunity-mediated antimicrobial responses with caseation during mycobacterium tuberculosis infection. J Immunol 2015; 194(2):664-77.
  24. Batoulis H, Recks MS, Addicks K, Kuerten S. Experimental autoimmune encephalomyelitis--achievements and prospective advances. Apis 2011; 119(12):819-30.
  25. Kant V, Gopal A, Pathak NN, Kumar P, Tandan SK, Kumar D. Antioxidant and anti-inflammatory potential of curcumin accelerated the cutaneous wound healing in streptozotocin-induced diabetic rats. Int Immunopharmacol 2014; 20(2):322-30.
  26. Zhao Q, Xie X, Fan Y, Zhang J, Jiang W, Wu X, et al. Phenotypic dysregulation of microglial activation in young offspring rats with maternal sleep deprivation-induced cognitive impairment. Sci Rep 2015; 5:9513.
  27. Myles IA, Pincus NB, Fontecilla NM, Datta SK. Effects of parental omega-3 fatty acid intake on offspring microbiome and immunity. PLoS One 2014; 9(1):e87181.
  28. Spera PA, Ellison JA, Feuerstein GZ, Barone FC. IL-10 reduces rat brain injury following focal stroke. Neurosci Lett 1998; 251(3):189-92.
  29. Lim A, Krajina K, Marsland AL. Peripheral inflammation and cognitive aging. Mod Trends Pharmacopsychiatry 2013; 28:175-87.
  30. Kuo HK, Yen CJ, Chang CH, Kuo CK, Chen JH, Sorond F. Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol 2005; 4(6):371-80.
  31. Bettcher BM, Wilheim R, Rigby T, Green R, Miller JW, Racine CA, et al. C-reactive protein is related to memory and medial temporal brain volume in older adults. Brain Behav Immun 2012; 26(1):103-8.
  32. Morrisette-Thomas V, Cohen AA, Fülöp T, Riesco É, Legault V, Li Q, et al. Inflamm-aging does not simply reflect increases in pro-inflammatory markers. Mech Ageing Dev 2014; 139:49-57.
  33. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189.
  34.  Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53:695.
  35. Roberts R, Knopman DS. Classification and epidemiology of MCI. Clin Geriatr Med 2013; 29(4):753-72.
  36. Wang RT, Jin D, Li Y, Liang QC. Decreased mean platelet volume and platelet distribution width are associated with mild cognitive impairment and Alzheimer's disease. J Psychiatr Res 2013; 47(5):644-9.
  37. Zheng M, Chang B, Tian L, Shan C, Chen H, Gao Y, et al. Relationship between inflammatory markers and mild cognitive impairment in Chinese patients with type 2 diabetes: a case-control study. BMC Endocr Disord 2019; 19(1):73.
  38. Wang J, Li XB, Huang P, Huang MY, Gu XJ. Change of Peripheral Blood Treg/Thl7 in Cognitive Impairment with Chronic Renal Failure Patients. Cell Physiol Biochem 2018; 45(1):281-90.
  39. Cao X, Chen P. Changes in Serum Amyloid A (SAA) and 8-OHdG in Patients with Senile Early Cognitive Impairment. Med Sci Monit 2020; 26:e919586.
  40. Shen XN, Lu Y, Tan CTY, Liu LY, Yu JT, Feng L, et al. Identification of inflammatory and vascular markers associated with mild cognitive impairment. Aging (Albany NY) 2019; 11(8):2403-19.
  41. Ridker PM, Morrow DA. C-reactive protein, inflammation, and coronary risk. Cardiol Clin 2003; 21(3):315-25.
  42. Stephens S, Kenny RA, Rowan E, Allan L, Kalaria RN, Bradbury M, et al. Neuropsychological characteristics of mild vascular cognitive impairment and dementia after stroke. Int J Geriatr Psychiatry 2004; 19(11):1053-7.
  43. Gorska-Ciebiada M, Saryusz-Wolska M, Borkowska A, Ciebiada M, Loba J. Serum levels of inflammatory markers in depressed elderly patients with diabetes and mild cognitive impairment. PLoS One 2015; 10(3):e0120433.
  44. Wang L, Wang F, Liu J, Zhang Q, Lei P. Inverse Relationship between Baseline Serum Albumin Levels and Risk of Mild Cognitive Impairment in Elderly: A Seven-Year Retrospective Cohort Study. Tohoku J Exp Med 2018; 246(1):51-7.
  45. Wennberg AMV, Hagen CE, Machulda MM, Knopman DS, Petersen RC, Mielke MM. The Cross-sectional and Longitudinal Associations Between IL-6, IL-10, and TNFα and Cognitive Outcomes in the Mayo Clinic Study of Aging. J Gerontol A Biol Sci Med Sci 2019; 74(8):1289-95.
  46. Kim SM, Song J, Kim S, Han C, Park MH, Koh Y, et al. Identification of peripheral inflammatory markers between normal control and Alzheimer's disease. BMC Neurol 2011; 11:51.
  47. Fu J, Duan J, Mo J, Xiao H, Huang Y, Chen W, et al. Mild Cognitive Impairment Patients Have Higher Regulatory T-Cell Proportions Compared With Alzheimer's Disease-Related Dementia Patients. Front Aging Neurosci 2020; 12:624304.